November 10, 2025 — Leads & Copy —
South San Francisco, Calif. — Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company, will participate in three investor conferences in November and December.
Christine Cassiano, EVP, Chief Corporate Affairs & Brand Strategy Officer at Allogene, can be reached for further information at Christine.Cassiano@allogene.com.
The conferences are:
- TD Cowen’s Immunology & Inflammation Virtual Summit:
Wednesday, November 12, 1:30PM PT/4:30PM ET - Jefferies Global Healthcare Conference in London:
Tuesday, November 18, 2:00AM PT/5:00AM ET/10:00AM GMT - Piper Sandler 37th Annual Healthcare Conference:
Tuesday, December 2, 9:00AM PT/12:00PM ET
Allogene is focused on pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease. The company’s “off-the-shelf” CAR T cell product candidates aim to deliver readily available cell therapy on-demand, more reliably, and at greater scale to more patients.
Webcasts, if available, will be posted on Allogene’s website under the Investors tab in the News and Events section. Replays will be available for approximately 30 days following the live webcasts.
This press release contains forward-looking statements regarding Allogene’s ability to develop and deliver allogeneic CAR T products for cancer and autoimmune disease on-demand, reliably, and at scale. These statements are subject to risks and uncertainties, including those related to novel technologies, regulatory approval, and other factors detailed in Allogene’s filings with the SEC, including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2025.
Allogene assumes no obligation to update these statements.
AlloCAR T™ is a trademark of Allogene Therapeutics, Inc.
Source: Allogene Therapeutics, Inc.
